Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of SVT-40776 vs tolterodine and placebo in overactive bladder
2006-001378-26Phase 2Completed
- Sponsor
- Laboratorios Salvat
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tarafenacin in overactive bladder (OAB) (5 arms), sponsored by Laboratorios Salvat. Primary endpoint: Change in number of micturitions per 24 hours. Started May 2006; status: completed.
02
Drugs
tarafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2006-001378-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001378-26.